New hopes in IPR

The U.S. Supreme Court dashed biopharma’s hopes that the inter partes review system will quickly disappear, and threw a monkey wrench into the U.S. Patent and Trademark Office’s procedures for streamlining the adjudication of IPR petitions.

Yet both decisions delivered on April 24 suggest avenues for the biopharma industry to attack aspects of the inter partes review (IPR) system that it believes unfairly weaken patent protections on innovative medicines. ...